Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
SemperVirens Venture Capital

SemperVirens Venture Capital

SemperVirens is a San Mateo, California-based venture capital firm focused on investments in workforce, health, and financial technologies.

Overview

SemperVirens is an early stage venture capital firm focused on investing in technology for work, health, and financial wellness. This includes a focus on company's which has products sold to or through the employer, including workplace technology, health technology, financial technology, and insurance technology. The firm is based in San Mateo, California.

Ecosystem

SemperVirens is an "ecosystem fund" working with a variety of investors, operators, consultants, accelerators, and industry analysts. Through this ecosystem, the firm works to source deal flows, real-time insights into buying patterns, market needs, and post-investment distribution for portfolio companies. This ecosystem includes an Executive Advisory Board, a Healthcare Advisory Board, and a group of HR Venture Advisors.

The board members include current and former CHROs of Fortune 500 companies, and these boards work to help portfolio companies navigate larger organizations and build their products. The HR Venture Advisors are all from senior leadership positions at public companies; the advisors act as end-buyers to provide feedback on market needs and product functionality for portfolio companies. Other investors who work with SemperVirens include founders with public companies in healthcare, workforce, and financial technology; representatives from consulting firms in those focus areas; healthcare executives, and sales, marketing, and customer success leaders from companies in focus areas.

Others in the SemperVirens investing ecosystem include strategic partnerships. These include partnerships with consulting firms and investment firms to help with portfolio companies and future investments. This includes partnerships with the following:

  • PeopleTech Partners
  • Sequoia
  • SHRM
  • EHR
  • Insurtech Connect
  • HR Transform
  • Peer 150 Human Resources
Investment approach

SemperVirens invests based on three core principles: Access, Analyze, and Amplify. For Access, this refers to the firm working to connect portfolio companies with stakeholders, channel partners, and end-buyers in SemperVirens network in order to develop meaningful relationships in the ecosystem and create value for portfolio companies and partnered companies.

For Analyze, this refers to the use of advisors, investors, and partners to help SemperVirens identify new opportunities, possible product transformations, and product-market fits with potential buyers before investing. And Amplify refers to SemperVirens proposed access to over 1500 companies across SMB, mid-market, and Fortune 500 companies that can help portfolio companies grow and provide them a market for selling products or services.

Timeline

November 5, 2021
Fountain raises $85 million in Series C funding in a round led by SoftBank Vision Fund 2, and with participation from SemperVirens Venture Capital, among others.
November 2, 2021
Hone, a human-powered platform for leadership training, nabs $16 million in Series A funding round led by F-Prime Capital and with participation from SemperVirens Venture Capital, among others.
October 7, 2021
SemperVirens Venture Capital announces investment in Praisidio
September 29, 2021
SemperVirens Venture Capital announces investment in Cocoon
August 24, 2021
Bravely raises $15 million in Series A funding round led by Telescope Partners and with participation from SemperVirens Venture Capital, among others.
April 19, 2021
SemperVirens Venture Capital announces investment in Mathison
March 2, 2021
SemperVirens Venture Capital announces investment in Murmur
January 26, 2021
SemperVirens Venture Capital announces Executive Advisory Board, focused on the future of work.

Invested in

Patents

Funding Rounds Participated In

Further Resources

Title
Author
Link
Type
Date

References

Golden logo
By using this site, you agree to our Terms & Conditions.